|
EMERYVILLE, Calif., Nov. 18 /PRNewswire/ -- KineMed, Inc., a platform-
based drug development and advanced medical diagnostics company, presented
results at 11:50 AM (PST) today from their insulin resistance program at the
3rd Annual World Congress on the Insulin Resistance Syndrome held in San
Francisco from November 17th-19th.
As part of the session entitled "Recent Developments in Identifying
Patients with Insulin Resistance," the Company presented data from a study
describing and validating the insulin resistance test (the deuterated glucose
disposal test or 2H-GDT), including comparison with the traditional
hyperinsulinemic-euglycemic glucose clamp method. The 2H-GDT was first
demonstrated to detect insulin resistance in animal models due to both genetic
and dietary factors, and to quantify the insulin sensitizing response to drugs
(rosiglitazone and metformin). Data on beta-cell compensation to insulin
resistance is also provided by this test, and differences were detected
between strains of animals. Next, a study was performed in lean individuals
and subjects with Metabolic Syndrome to demonstrate the reliability of the
assay in measuring insulin resistance in humans. Measurements taken in 17
subjects showed a remarkably close correlation between the KineMarker(TM) and
clamp data (R = 0.95) and documented insulin resistance in Metabolic Syndrome.
The company also presented data quantifying the presence and degree of insulin
resistance in a survey of lean and overweight subjects.
David Fineman, President and CEO of KineMed, commented, "This technology
provides drug developers and clinicians a clinically feasible method of
measuring insulin resistance which is, importantly, highly correlated with the
labor intensive, expensive and impractical hyperinsulinemic-euglycemic glucose
clamp method. KineMeds insulin resistance KineMarker(TM) characterizes
glucose homeostatic status and susceptibility to developing type 2 diabetes.
Our results show that KineMeds KineMarker allows pancreatic compensation to
be measured at the same time that the degree of insulin resistance is
measured. Applications include development of new drugs targeting pre-
diabetes, diabetes and the metabolic syndrome."
KineMed KineMarker(TM) Product Programs in Diabetes
KineMeds proprietary in vivo KineMarker(TM) assays provide new, sensitive
and high-throughput measures of several key metabolic pathways involved in the
pathogenesis and treatment of diabetes and other metabolic disorders. These
assays can be used in clinical as well as pre-clinical settings.
KineMeds insulin resistance KineMarker(TM) is much easier to apply and
less labor-intensive than the traditional hyperinsulinemic-euglycemic glucose
clamp method, which is the current "gold-standard" in the field. Clinical
trial efficiency and patient comfort are thereby improved considerably.
Subjects drink a specially labeled glucose-containing drink, and two blood
draws over a three hour period.
KineMeds second product program in diabetes offers a pre-clinical measure
of pancreatic beta-cell proliferation. This assay provides a new, less labor-
intensive, more sensitive and much more highly reproducible measure of
insulin-secreting cell (pancreatic beta-cell) regeneration in pre-clinical
models. New drug candidates that target the regeneration of pancreatic beta-
cells are being developed, but previous methods could only measure pancreatic
beta-cell mass by histology rather than the true regeneration rate of beta-
cells, as KineMeds test achieves.
About KineMed, Inc.
KineMed, Inc. provides a proprietary set of tools for measuring the
dynamics of molecular and cellular response to drugs in the intact organism,
both in animals and humans. KineMeds technology is ideally suited to enable
the discovery of entirely new, unanticipated uses for compounds (an approach
called repurposing or repositioning) by screening for activity in vivo across
a wide variety of disease states. The breadth of therapeutic targets covered
by KineMarker(TM) assays allows high-throughput screening in conditions beyond
those typically evaluated. KineMeds technology expedites the drug
development process and provides real-time insight into conditions including
metabolic disorders, cancer, and diseases of inflammation and
neurodegeneration.
For further information about KineMed, please visit:
http://www.kinemed.com/ .
|
|
